Regeneron Pharmaceuticals Q3 2026 Earnings Conference Call - REGENERON PHARMACEUTICALS INC

Financial Performance:

• Total revenue grew 36% year-over-year to $5.1 billion in Q3 2026, driven by a 70% increase in non-GAAP earnings per share to $20.07 and net income of $2.2 billion.
• Sanofi collaboration revenue reached an all-time high of $2.6 billion in collaboration profits, with total collaboration revenue hitting $21.7 billion, including the first full recognition of Regeneron's share of profits from the expanded alliance.
• Product-specific net sales: Dupixent reached a record $6.5 billion globally (35% growth); ILIA-HD hit a high of $700 million (62% growth); Libtayo reached $550 million (51% growth).
• Free cash flow generated was $2.9 billion through the first nine months of 2026; cash and marketable securities net of debt stood at $16.2 billion.
• Operating expenses: R&D was $1.7 billion; SG&A was $588 million (up 9%); effective tax rate was 15%.
• Capital deployment included $2.3 billion in share repurchases (3.2 million shares) in the first nine months, with full-year expectations of approximately $3 billion.
• Alaris royalty revenue included a non-recurring $60 million cumulative catch-up adjustment.

Guidance and Future Outlook:

• 2027 R&D expense is expected to increase by a mid-teens percentage compared to 2026, reflecting investments in advancing multiple registrational programs.
• 2027 effective tax rate is projected to face 100–200 basis points of upward pressure relative to 2026.
• The company anticipates initiating more than 15 Phase 3 trials in 2026, with pivotal readouts expected from the knee replacement program in 2027 and other anticoagulation programs in 2028.
• Full-year 2026 net sales guidance was refined with modest adjustments; ILIA-HD is expected to deliver over 50% full-year growth, while ILIA-U.S. faces sequential demand decline in Q4.
• No revenue is anticipated for Inmazeb in Q4 2026 due to the new Barter agreement supplying the U.S. government; additional doses will be supplied through 2031 starting late 2027.
• A $1 billion upfront payment from the expanded Sanofi alliance is expected to be recorded in Q4 2026 collaboration revenue.

Business Segments and Product Lines:

• Dupixent: Global sales of $6.5 billion, led by U.S. growth of 40% to over $5 billion; expanding into 9 indications with strong uptake in COPD and chronic spontaneous urticaria.
• ILIA Franchise: ILIA-HD (60-70% of franchise sales) is up 62% to $700 million, driven by extended dosing and label enhancements for RVO; ILIA-U.S. saw a 41% decline to $400 million due to competition from flibbercept biosimilars.
• Libtayo: Global sales of $550 million; U.S. sales up 81% to nearly $400 million, leading in non-melanoma skin cancer and second in non-small cell lung cancer; positive CHMP opinion received for every-six-week dosing.
• New Launches: Passia (for FOP) and Otarmony (for genetic hearing loss) recently launched with promising initial progress; FKESCA (rare disease) up 28% to $55 million.
• Pipeline Highlights:
  • Simdisiran (C5): FDA decision expected in November for generalized myasthenia gravis (GMG); first and only quarterly subcutaneous siRNA therapy for this indication.
  • SideB (MASH): Preclinical/early clinical data shows 70% liver fat reduction with a single dose; rapidly advancing to registration-enabling studies.
  • POTS: Initial Phase 2 data supports potential for first FDA-approved treatment; pivotal study planned for next year.
  • Ubermab (Ovarian Cancer): 70% objective response rate in low-grade serous ovarian cancer; enrolling registrational cohort.
  • Linazific & Odrinextamab: Late-stage bispecifics in multiple myeloma and lymphoma with pivotal trials planned for 2027–2028.
  • Sanofi Alliance: Expanded to include four next-generation long-acting antibodies (IL-4, IL-13, IL-4/13 bispecific, IL-4RA) designed for less frequent dosing with 50-50 profit sharing.

Market and Competitive Landscape:

• Dupixent remains the leading biologic in eight of nine FDA-approved indications, with strong gross-to-net favorability and broad physician adoption.
• ILIA-HD is positioning as best-in-class in anti-VEGF therapy, though facing headwinds from flibbercept 2mg biosimilar launches; pre-filled syringe approval expected by year-end to support momentum.
• Libtayo is the only NCCN Category 1 preferred immunotherapy for adjuvant CSCC and the second most prescribed for NSCLC.
• Competitive differentiation emphasized: Regeneron's naturally derived, non-engineered antibodies (Sanofi alliance) are expected to outperform heavily engineered competitors regarding immunogenicity and safety.
• SideB program offers a unique advantage over competitors (e.g., GLP-1s) by directly targeting a genetically validated liver pathway rather than indirect weight loss mechanisms.

Risks and Challenges:

• Competition: Continued pressure from biosimilars in the ILIA franchise and the emerging landscape of long-acting biologics in type 2 inflammation.
• Pricing & Reimbursement: Ongoing pricing pressures affecting ILIA-U.S. sequential performance and the need for favorable gross-to-net adjustments.
• Execution Risk: Management acknowledged challenges in scaling commercial operations across a broad, diverse pipeline spanning many therapeutic areas (neurology, oncology, rare diseases).
• Regulatory Uncertainty: Pivotal trial outcomes and FDA approval timelines for Simdisiran, SideB, and other late-stage assets carry inherent risks.
• R&D Costs: Anticipated increase in R&D spending to support the advancing pipeline.

Management Commentary and Tone:

• Tone was highly confident and optimistic, describing the quarter as "exceptional" with "record levels" of commercial performance.
• Emphasis on the success of the "disease-agnostic" R&D approach leveraging human genetics to identify and validate targets (e.g., SideB).
• Management expressed strong belief in the expanded Sanofi alliance as a platform for leading the next era of type 2 inflammation therapies.
• Dr. Schleifer highlighted the synergy between the broad commercial footprint (spanning nearly all relevant specialties) and the diverse pipeline.

Analyst Questions and Answers:

• SideB Differentiation: George Yancopoulos confirmed SideB uniquely addresses a genetic driver of MASH, achieving 70% liver fat reduction rapidly, a result he called "game-changing" and unmatched by indirect mechanisms.
• Simdisiran Launch: Marion McCourt confirmed the neurology team is ready for launch pending November approval, with no specific details on launch strategy disclosed.
• Sanofi Alliance Scope: Management confirmed the alliance is open to adding assets like Stat6 orals but emphasized that long-acting injectables offer superior convenience and efficacy profiles compared to daily pills.
• Business Development Strategy: Len Schleifer stated Regeneron is agnostic on acquisition stage (early vs. advanced) but prioritizes internal R&D due to its high productivity; they will only acquire assets that offer distinct strategic fit or superior science.
• Next-Gen Dupixent: Four next-gen antibodies are in development with potential for different indications; they are designed to avoid the immunogenicity risks associated with heavily engineered antibodies.
• POTS and Obesity: Management noted that entering the obesity market requires a truly differentiated mechanism (e.g., lipid/cardiovascular risk reduction or muscle preservation) rather than competing on marginal weight loss improvements.

Other Key Points:

• The expanded Sanofi alliance includes 50-50 sharing of development costs and global profits for four new long-acting antibodies, with Sanofi leading commercialization and Regeneron leading R&D.
• A new BCMA by CD3 bispecific targeting IgE-producing plasma cells is planned to start in Phase 1 studies in the first half of 2027, potentially building on the Dupixent combination approach for food allergies.
• The company has a "passive" strategy on Inmazeb revenue recognition for 2026 due to the barter agreement, shifting focus to future supply obligations.
• The Regeneron Genetics Center's role in drug discovery was highlighted as a core competitive advantage, specifically for the SideB MASH program.